2.35Open2.35Pre Close0 Volume88 Open Interest5.00Strike Price0.00Turnover0.00%IV-632.04%PremiumDec 20, 2024Expiry Date4.64Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet